A Phase 1 interventional study of bomedemstat and carbamazepine in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-18.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Researchers have designed a study medicine called bomedemstat (MK-3543) as a new way to treat certain rare blood diseases.
The purpose of this study is to learn what happens to bomedemstat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to bomedemstat in the body when it is given alone and after multiple doses of another medicine called carbamazepine (CBZ).
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
History or presence of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of bomedemstat will be administered On Day 1 of Period 1. There will be a washout of 7 days between bomedemstat dosing in Period 1 and the first carbamazepine (CBZ) dose in Period 2. In Period 2, CBZ will be administered twice daily (BID) for 17 consecutive days, with a single dose of bomedemstat coadministered with the morning dose on Day 14.
Drug: bomedemstat · Drug: carbamazepine
Oral tablet
Also known as: MK-3543
Oral extended-release capsule
Area under the concentration versus time curve from 0 to infinity (AUC0-inf) of bomedemstat
AUC0-inf for bomedemstat in plasma will be determined
Time frame: Predose and at designated timepoints up to 168 hours postdose
Number of participants who experience one or more adverse events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 66 days
Number of participants who discontinue study treatment due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 25 days
Area under the concentration versus time curve from 0 to the time of the last quantifiable sample (AUC0-last) of bomedemstat
AUC0-last for bomedemstat in plasma will be determined
Time frame: Predose and at designated timepoints up to 168 hours postdose
Area under the concentration versus time curve from 0 to 24 hours after dosing (AUC0-24) of bomedemstat
AUC0-24 for bomedemstat in plasma will be determined
Time frame: Predose and at designated timepoints up to 24 hours postdose
Maximum observed concentration (Cmax) of bomedemstat
Cmax for bomedemstat in plasma will be determined
Time frame: Predose and at designated timepoints up to 168 hours postdose
Maximum observed concentration 24 hours after dosing (C24) bomedemstat
Cmax for bomedemstat in plasma will be determined
Time frame: Predose and at designated timepoints up to 24 hours postdose
Time to maximum concentration (Tmax) of bomedemstat
Tmax for bomedemstat in plasma will be determined
Time frame: Predose and at designated timepoints up to 168 hours postdose
Apparent terminal half-life (t1/2) of bomedemstat
t1/2 for bomedemstat in plasma will be determined
Time frame: Predose and at designated timepoints up to 168 hours postdose
Apparent clearance (CL/F) of bomedemstat
CL/F for bomedemstat in plasma will be determined
Time frame: Predose and at designated timepoints up to 168 hours postdose
Apparent volume of distribution during terminal phase (Vz/F) of bomedemstat in plasma
Vz/F for bomedemstat in plasma will be determined
Time frame: Predose and at designated timepoints up to 168 hours postdose
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Oct 2024 to primary completion in Feb 2025, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bomedemstat